Bank Of America Corp Tenaya Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 125,686 shares of TNYA stock, worth $280,279. This represents 0.0% of its overall portfolio holdings.

Number of Shares

125,686

Previous 225,869 44.35%

Holding current value

$280,279

Previous $1.18 Million 67.06%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.72 - $4.99 $272,497 - $499,913	-100,183 Reduced 44.35%	125,686 $389,000
Q1 2024 May 15, 2024	BUY	$2.88 - $6.8 $221,955 - $524,062	77,068 Added 51.79%	225,869 $1.18 Million
Q4 2023 Feb 14, 2024	BUY	$1.73 - $3.39 $182,371 - $357,363	105,417 Added 242.99%	148,801 $482,000
Q2 2023 Aug 14, 2023	SELL	$2.64 - $7.64 $70,551 - $204,171	-26,724 Reduced 38.12%	43,384 $254,000
Q1 2023 May 12, 2023	SELL	$1.92 - $3.59 $15,260 - $28,533	-7,948 Reduced 10.18%	70,108 $199,000
Q4 2022 Feb 10, 2023	BUY	$1.68 - $3.19 $88,131 - $167,344	52,459 Added 204.94%	78,056 $156,000
Q3 2022 Nov 14, 2022	BUY	$2.9 - $5.88 $23,028 - $46,693	7,941 Added 44.98%	25,597 $74,000
Q2 2022 Aug 12, 2022	SELL	$5.01 - $14.12 $3,251 - $9,163	-649 Reduced 3.55%	17,656 $99,000
Q1 2022 May 16, 2022	BUY	$9.41 - $19.3 $33,556 - $68,823	3,566 Added 24.19%	18,305 $216,000
Q4 2021 Feb 08, 2022	BUY	$18.41 - $29.58 $252,290 - $405,364	13,704 Added 1324.06%	14,739 $279,000
Q3 2021 Nov 15, 2021	BUY	$15.35 - $26.66 $15,887 - $27,593	1,035 New	1,035 $21,000

Others Institutions Holding TNYA

# of Institutions

Shares Held

56M

Call Options Held

30.3K

Put Options Held

600

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $92.2M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Tenaya Therapeutics, Inc. Transaction History